Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $685,872 - $852,192
-3,600 Reduced 52.94%
3,200 $741,000
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $805,676 - $1.02 Million
3,800 Added 126.67%
6,800 $1.47 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $422,921 - $509,086
1,900 Added 172.73%
3,000 $776,000
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $278,630 - $314,479
1,100 New
1,100 $282,000
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $1.1 Million - $1.26 Million
4,300 New
4,300 $1.2 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.